Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

home / authors / mark-freedman-md

Professor of Medicine in Neurology, University of Ottawa; Director, Multiple Sclerosis Research Unit, Ottawa Hospital; Senior Scientist, Ottawa Hospital Research Institute

Articles

Do We Finally Have a Useful “Sed Rate” for Multiple Sclerosis?

Do We Finally Have a Useful “Sed Rate” for Multiple Sclerosis?

June 15th 2021

All agree that having a simple, standardized serum biomarker to measure disease activity would offer the greatest utility in treating a medical condition such as MS, which now has a variety of graded therapies available.

The Future of Managing Multiple Sclerosis

The Future of Managing Multiple Sclerosis

February 2nd 2021
Fumarates for Treatment of RMS

Fumarates for Treatment of RMS

January 26th 2021
S1P Receptor Modulators for Treatment of RMS

S1P Receptor Modulators for Treatment of RMS

January 21st 2021
Cladribine for Treatment of RMS

Cladribine for Treatment of RMS

January 20th 2021
Anti-CD20 Monoclonal Antibodies for Treatment of RMS

Anti-CD20 Monoclonal Antibodies for Treatment of RMS

January 18th 2021
Strategies for Choosing Initial Therapy in MS

Strategies for Choosing Initial Therapy in MS

January 15th 2021
OPTIMUM Phase 3 Trial: Secondary End Point Effect on Fatigue

OPTIMUM Phase 3 Trial: Secondary End Point Effect on Fatigue

January 12th 2021
TRIUMPHANT-MS Trial: Fatigue in MS

TRIUMPHANT-MS Trial: Fatigue in MS

January 5th 2021
Multiple Sclerosis Fatigue

Multiple Sclerosis Fatigue

January 4th 2021
QoL Issues in the Management of Multiple Sclerosis

QoL Issues in the Management of Multiple Sclerosis

January 1st 2021
Challenges in Optimally Treating Multiple Sclerosis

Challenges in Optimally Treating Multiple Sclerosis

December 31st 2020
Cerebrospinal Fluid in Diagnosing Multiple Sclerosis

Cerebrospinal Fluid in Diagnosing Multiple Sclerosis

December 28th 2020
Misdiagnosis of Multiple Sclerosis

Misdiagnosis of Multiple Sclerosis

December 25th 2020
Use of MRI in Diagnosing Multiple Sclerosis

Use of MRI in Diagnosing Multiple Sclerosis

December 23rd 2020
2017 Changes to the McDonald Criteria: Diagnosing Multiple Sclerosis

2017 Changes to the McDonald Criteria: Diagnosing Multiple Sclerosis

December 16th 2020
Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

November 24th 2020
COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

November 24th 2020
CLARITY Extension Trial: Disability Improvement With Cladribine

CLARITY Extension Trial: Disability Improvement With Cladribine

November 24th 2020
Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

November 24th 2020
Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

November 24th 2020
Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

November 24th 2020
Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

November 24th 2020
OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

November 24th 2020
OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

November 24th 2020
Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

November 24th 2020
Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

November 24th 2020
Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

November 24th 2020
OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

November 24th 2020
OLKIOS: Looking at Ofatumumab’s Continued Efficacy

OLKIOS: Looking at Ofatumumab’s Continued Efficacy

November 24th 2020
12>
© 2023 MJH Life Sciences

All rights reserved.